Aortic Valve Surgery in Patients with Infective Endocarditis: Mid-Term Follow-up of Patients Treated With the ST. Jude Medical Trifecta Valve
DOI:
https://doi.org/10.48729/pjctvs.283Keywords:
Infective endocarditis, Aortic Valve Surgery, Bioprosthesis, St. Jude Medical Trifecta valveAbstract
Background: It is particularly difficult to choose the appropriate prosthesis to treat infective endocarditis.
Objectives: To investigate the outcomes after aortic valve replacement with a stented bioprosthesis (Trifecta) in patients with active or previous infective endocarditis.
Methods: We performed a single-centre, retrospective study including consecutive patients with infective endocarditis who underwent aortic valve replacement between July 2011 and June 2019. Survival and reintervention were assessed as of December 2021. Hospital mortality was defined as death in-hospital or within 30-days of surgery. Kaplan-Meier method was used for time-to-event outcome assessment (all-cause mortality and reoperation). Data are median (minimum and maximum) or absolute (relative) frequencies.
Results: We included 51 patients, median age of 69 (40 to 87) years, 78% male. The median follow-up time was 5.4 years and the maximum was 10 years. Most patients (71%) had native valve infective endocarditis and 16% had previous endocarditis. Surgery was urgent in 82%. Hospital mortality occurred in 10 patients (20%). After excluding these patients, 1-, 3-, 6-, and 9-years cumulative survival rates were 93%, 78%, 72%, and 72%, respectively. There were five bioprosthesis-related reoperations: 4 due to endocarditis at 1-year, 3-years, and 5-years on follow-up (n=1, 1 and 2, respectively) and 1 due to non-structural deterioration, 6-years after surgery.
Conclusions: Despite the small sample size, this report supports a satisfactory performance profile of the Trifecta bioprosthesis in the treatment of infective endocarditis.
Downloads
References
Musci M, Siniawski H, Pasic M, Weng Y, Loforte A, Kosky S, et al. Surgical therapy in patients with active infective endocarditis: seven-year single centre experience in a subgroup of 255 patients treated with the Shelhigh® stentless bioprosthesis. European Journal of Cardio-Thoracic Surgery. 2008;34(2):410-7.
Cahill TJ, Prendergast BD. Infective endocarditis. Lancet. 2016;387(10021):882-93.
Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). European Heart Journal. 2015;36(44):3075-128.
Wang A, Gaca JG, Chu VH. Management Considerations in Infective Endocarditis: A Review. JAMA. 2018;320(1):72-83.
Bavaria JE, Desai ND, Cheung A, Petracek MR, Groh MA, Borger MA, et al. The St Jude Medical Trifecta aortic pericardial valve: results from a global, multicenter, prospective clinical study. J Thorac Cardiovasc Surg. 2014;147(2):590-7.
Mariscalco G, Mariani S, Bichi S, Biondi A, Blasio A, Borsani P, et al. St. Jude Medical Trifecta aortic valve: results from a prospective regional multicentre registry. J Cardiothorac Surg. 2015;10:169.
Goldman S, Cheung A, Bavaria JE, Petracek MR, Groh MA, Schaff HV. Midterm, multicenter clinical and hemodynamic results for the Trifecta aortic pericardial valve. J Thorac Cardiovasc Surg. 2017;153(3):561-9.e2.
Deutsch MA, Prinzing A, Fiegl K, Wottke M, Badiu CC, Krane M, et al. Early haemodynamic performance of a latest generation supra-annular aortic bioprosthesis: experience from a large single-centre series. Eur J Cardiothorac Surg. 2016;49(6):1691-8.
Phan K, Ha H, Phan S, Misfeld M, Di Eusanio M, Yan TD. Early hemodynamic performance of the third generation St Jude Trifecta aortic prosthesis: A systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2015;149(6):1567-75.e1-2.
Raimundo R, Moreira S, Saraiva F, Cerqueira RJ, Teixeira P, Salgueiro E, et al. Early and mid-term haemodynamic performance and clinical outcomes of St. Jude Medical TrifectaTM valve. J Thorac Dis. 2018;10(2):889-98.
Toyoda N, Itagaki S, Tannous H, Egorova NN, Chikwe J. Bioprosthetic Versus Mechanical Valve Replacement for Infective Endocarditis: Focus on Recurrence Rates. Ann Thorac Surg. 2018;106(1):99-106.
Sweeney MS, Reul GJ, Jr., Cooley DA, Ott DA, Duncan JM, Frazier OH, et al. Comparison of bioprosthetic and mechanical valve replacement for active endocarditis. J Thorac Cardiovasc Surg. 1985;90(5):676-80.
Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Jr., Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633-8.
Infective Endocarditis Surgery Cleveland clinic webpage [Available from: https://my.clevelandclinic.org/health/treat- ments/17125-infective-endocarditis-surgery.
Capodanno D, Petronio AS, Prendergast B, Eltchaninoff H, Vahanian A, Modine T, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2017;38(45):3382-90.
R Core Team. R: A language and environment for statistical computing. . R Foundation for Statistical Computing. (2019).
Moon MR, Miller DC, Moore KA, Oyer PE, Mitchell RS, Robbins RC, et al. Treatment of endocarditis with valve replacement: the question of tissue versus mechanical prosthesis. The Annals of thoracic surgery. 2001;71(4):1164-71.
Wos S, Jasinski M, Bachowski R, Piekarski M, Ceglarek W, Domaradzki W, et al. Results of mechanical prosthetic valve replacement in active valvular endocarditis. J Cardiovasc Surg (Torino). 1996;37(6 Suppl 1):29-32.
Delahaye F, Chu VH, Altclas J, Barsic B, Delahaye A, Freiberger T, et al. One-year outcome following biological or mechanical valve replacement for infective endocarditis. Int J Cardiol. 2015;178:117-23.
Malvindi PG, Olevano C, Luthra S, Tsang G, Barlow C, Ohri S. Outcomes of patients with acute prosthetic aortic valve endocarditis. Asian Cardiovasc Thorac Ann. 2021;29(4):268-77.
Schaefer A, Dickow J, Schoen G, Westhofen S, Kloss L, Al-Say- dali T, et al. Stentless vs. stented bioprosthesis for aortic valve replacement: A case matched comparison of long-term follow-up and subgroup analysis of patients with native valve endocarditis. PLoS One. 2018;13(1):e0191171.
Downloads
Published
How to Cite
License
Copyright (c) 2022 Portuguese Journal of Cardiac Thoracic and Vascular Surgery
This work is licensed under a Creative Commons Attribution 4.0 International License.
